Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Xencor, Inc. (XNCR : NSDQ)

• Company Description    Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. Number of Employees: 250

• Price / Volume Information    Yesterday's Closing Price: $9.28 Daily Weekly Monthly 20 Day Moving Average: 737,866 shares Shares Outstanding: 71.17 (millions) Market Capitalization: $660.47 (millions) Beta: 0.85 52 Week High: $27.24 52 Week Low: $7.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.59% -5.28% 12 Week -4.33% -19.53% Year To Date -59.62% -62.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 465 NORTH HALSTEAD STREET SUITE 200 - PASADENA,CA 91107 USA ph: 626-305-5900 fax: 626-305-0350 investors@xencor.com http://www.xencor.com

• General Corporate Information    Officers Bassil I. Dahiyat - Chief Executive Officer; President and Director Bart Jan Cornelissen - Sr. Vice President & Chief Financial Officer A. Bruce Montgomery - Director Kurt Gustafson - Director Kevin C. Gorman - Director Peer Information Xencor, Inc. (GSAC) Xencor, Inc. (CASI) Xencor, Inc. (ALCD.) Xencor, Inc. (OMNN) Xencor, Inc. (CGPI.) Xencor, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98401F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 71.17 Most Recent Split Date: (:1) Beta: 0.85 Market Capitalization: $660.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.77 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 33.82% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.03 Price/Cash Flow: - Price / Sales: 5.83 EPS Growth vs. Year Ago Period: 40.54% vs. Previous Quarter: -6.45% Sales Growth vs. Year Ago Period: 155.62% vs. Previous Quarter: -38.00% ROE 06/30/25 - - 03/31/25 - -31.94 12/31/24 - -35.55 ROA 06/30/25 - - 03/31/25 - -22.19 12/31/24 - -24.36 Current Ratio 06/30/25 - - 03/31/25 - 5.89 12/31/24 - 6.61 Quick Ratio 06/30/25 - - 03/31/25 - 5.89 12/31/24 - 6.61 Operating Margin 06/30/25 - - 03/31/25 - -181.17 12/31/24 - -240.91 Net Margin 06/30/25 - - 03/31/25 - -181.17 12/31/24 - -240.91 Pre-Tax Margin 06/30/25 - - 03/31/25 - -184.70 12/31/24 - -212.61 Book Value 06/30/25 - - 03/31/25 - 8.99 12/31/24 - 9.63 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.16 12/31/24 - 0.17 Debt-to-Capital 06/30/25 - - 03/31/25 - 13.73 12/31/24 - 14.59

Powered by Zacks Investment Research ©